Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
35 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
17 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
77.4 rhumatos / 100 000 hab. — département bien doté
17ans d'exercice (thèse 2009)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Effet modulateur des acides gras oméga-3, de l'argine et de la glutamine dans 3 modèles d'inflammation intestinale
Direction : Pierre Déchelotte
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
5
5 articles ont été cités au moins 5fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
485
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
9
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
5
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
CABINET DU DR AKTHAM HASSAN
POLE SANTE SUD 28 RUE DE GUETTELOUP, 72100 LE MANS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Drug development research · 2023
AbstractThe strategy of utilizing nitrogen compounds in various biological applications has recently emerged as a powerful approach to exploring novel classes of therapeutics to face the challenge of diseases. A series of pyrazolo[1,5‐a]pyrimidine‐based compounds 3a–l and 5a–f were prepared by the direct cyclo‐condensation reaction of 5‐amino‐1H‐pyrazoles 1a, b with 2‐(arylidene)malononitriles and 3‐(dimethylamino)‐1‐aryl‐prop‐2‐en‐1‐ones, respectively. The structures of the new pyrazolo[1,5‐a]pyrimidine compounds were confirmed via spectroscopic techniques. The in vitro biological activities of all pyrazolo[1,5‐a]pyrimidines 3a–l and 5a–f were evaluated by assaying total antioxidant capacity, iron‐reducing power, the scavenging activity against 1‐diphenyl‐2‐picryl‐hydrazyl (DPPH) and 2, 2'‐azinobis‐(3‐ethylbenzothiazoline‐6‐sulfonic acid) (ABTS) radicals, anti‐diabetic, anti‐Alzheimer, and anti‐arthritic biological activities. All compounds displayed good to potent bioactivity, and three compounds 3g, 3h, and 3l displayed the most active derivatives. Among these derivatives, compound 3l exhibited the highest antioxidant (total antioxidant capacity [TAC] = 83.09 mg gallic acid/g; iron‐reducing power [IRP] = 47.93 µg/ml) and free radicals scavenging activities with (DPPH = 18.77 µg/ml; ABTS = 40.44%) compared with ascorbic acid (DPPH = 4.28 µg/ml; ABTS = 38.84%). Furthermore, compound 3l demonstrated the strongest inhibition of α‐amylase with a percent inhibition of 72.91 ± 0.14 compared to acarbose = 67.92 ± 0.09%. Similarly, it displayed acetylcholinesterase inhibition of 62.80 ± 0.06%. However, compound 3i showed a significantly higher inhibition percentage for protein denaturation and proteinase at 20.66 ± 0.00 and 26.42 ± 0.06%, respectively. Additionally, some in silico ADMET properties were predicted and studied. Finally, molecular docking simulation was performed inside the active site of α‐amylase and acetylcholinesterase to study their interactions.
Rheumatology international · 2023
Abstract The current systematic review aimed to document published cases of femoral head avascular necrosis (FHAVN) post-COVID-19, to report the COVID-19 disease characteristics and management patients received, and to evaluate how the FHAVN were diagnosed and treated among various reports. A systematic literature review was performed per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines through a comprehensive English literature search on January 2023 through four databases (Embase, PubMed, Cochrane Library, and Scopus), including studies reporting on FHAVN post-COVID-19. Fourteen articles were included, ten (71.4%) were case reports, and four (28.6%) case series reported on 104 patients having a mean age of 42.2 ± 11.7 (14:74) years, in which 182 hip joints were affected. In 13 reports, corticosteroids were used during the COVID-19 management plan for a mean of 24.8 ± 11 (7:42) days, with a mean prednisolone equivalent dose of 1238.5 ± 492.8 (100:3520) mg. A mean of 142.1 ± 107.6 (7:459) days passed between COVID-19 diagnosis and FHAVN detection, and most of the hips were stage II (70.1%), and concomitant septic arthritis was present in eight (4.4%) hips. Most hips (147, 80.8%) were treated non-surgically, of which 143 (78.6%) hips received medical treatment, while 35 (19.2%) hips were surgically managed, 16 (8.8%) core decompression, 13 (7.1%) primary THA, five (2.7%) staged THA and three (1.6%) had first stage THA (debridement and application of antibiotic-loaded cement spacer). The outcomes were acceptable as regards hip function and pain relief. Femoral head avascular necrosis post-COVID-19 infection is a real concern, primarily attributed to corticosteroid usage, besides other factors. Early suspicion and detection are mandatory, as conservative management lines are effective during early stages with acceptable outcomes. However, surgical intervention was required for progressive collapse or patients presented in the late stage.
PloS one · 2024
Background To describe Purtscher’s and Purtscher-like retinopathy clinical features, etiologies, management options, and visual outcomes. Methods Our protocol was registered on PROSPERO [registration number: CRD42023406843]. Seven online databases were searched: PubMed, Scopus, Medline, ScienceDirect, CENTRAL, clinicaltrials.gov, and Google Scholar. Original articles were included if they reported at least one subject diagnosed with Purtscher’s or Purtscher-like retinopathy. The primary outcome is to describe the clinical features of Purtscher and Purtscher-like retinopathies, including etiologies, results of related investigations, management lines, and visual outcomes. All analyses were conducted with the use of Statistical Package for Social Sciences (SPSS) version 27 (IBM SPSS Corp, SPSS Statistics ver. 26, USA) and Cochrane’s RevMan software. The methodological quality of included studies was assessed using the NIH quality assessment tools. Results A total of 114 articles were included, describing 168 cases of Purtscher’s and Purtscher-like retinopathy. Patients were evenly distributed between males (50.89%) and females (49.11%). Average age of patients was 34.62 years old. Trauma was the leading cause of retinopathy, being reported in 39.88% of our patients, followed by systemic lupus erythematosus (SLE) (13.1%) and acute pancreatitis (11.9%). Bilateral symptoms were reported in 57.7% of patients with centrally blurred vision being the most complained symptom (OS: 34.32% and OD: 18%). 75% of patients elicited bilateral retinal findings. Cotton-wool spots were of highest prevalence (58%). Purtscher flecken was seen in 53% of patients. Macular edema was seen in 13% of patients. Overall, patients had a favorable prognosis (53%). Conclusion Purtscher’s and Purtscher-like retinopathies are rare sight-threatening retinopathies that develop most commonly following trauma or other systemic diseases as SLE and acute pancreatitis. Little data is available regarding these conditions, and available data is of low quality. Patients develop bilateral disease in approximately 50% of cases, and several retinal findings are observed, with no specific tendency. Most observed signs are cotton-wool spots in around 55% of patients and Purtscher flecken in 51% of patients. Patients spontaneously recovered, although data is not conclusive. No clear prognostic value of etiological factors is identified, and further research is required in this regard.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Clinical neurophysiology practice · 2025 · Letter
Elshony H, Aly MH, Mohammed A, Hassan AM, et al.
Clinical neurophysiology practice · 2025 · Journal Article
Elshony H, Aly MH, Mohammed A, Hassan AM, et al.
Journal of education and health promotion · 2025 · Journal Article
Doweir AM, Mashaal A, Basha SAZ, Abdelhamid DMM, et al.
Medicina (Kaunas, Lithuania) · 2024 · Journal Article
Hassan AB, Almarabheh A, Almekhyal A, AlAwadhi DA, et al.
Fitoterapia · 2024 · Journal Article
Mettwally WSA, Hussein RA, Abdel Jaleel GA, Hassan A, et al.
Artificial cells, nanomedicine, and biotechnology · 2024 · Journal Article
Belal A, Almalki AH, Farghali AA, Mahmoud R, et al.
JPMA. The Journal of the Pakistan Medical Association · 2024 · Case Reports
Zubair A, Qureshyl A, Hassan A
JPMA. The Journal of the Pakistan Medical Association · 2024 · Case Reports
Zubair A, Gill SM, Hassan A
Antibiotics (Basel, Switzerland) · 2023 · Journal Article
Almalki AH, Hassan WH, Belal A, Farghali A, et al.
Pharmaceuticals (Basel, Switzerland) · 2023 · Journal Article
Belal A, Mahmoud R, Mohamed EE, Farghali A, et al.
Scientific reports · 2023 · Journal Article
Hassan AM, Haridy MA, Shoaeir MZ, Abdel-Aziz TM, et al.
Clinical nuclear medicine · 2023 · Journal Article
Gill SM, Hassan A
Drug development research · 2023 · Journal Article
Hassan AS, Morsy NM, Aboulthana WM, Ragab A
Journal of neuromuscular diseases · 2022 · Journal Article
Al Shehri A, Al-Asmi A, Al Salti AM, Almadani A, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026 · Journal Article
Abdalbary M, Amin AM, Elaraby A, Hassan A
Skeletal radiology · 2025 · Journal Article
McDonald SM, Felfeliyan B, Hassan A, Küpper JC, et al.
Current eye research · 2025 · Journal Article
Abu Serhan H, Hassan AK, Rifai M, Elsayed RA, et al.
Current eye research · 2025 · Journal Article
Abu Serhan H, Hassan AK, Rifai M, Elsayed RA, et al.
PloS one · 2024 · Journal Article
Serhan HA, Abuawwad MT, Taha MJJ, Hassan AK, et al.
Cureus · 2023 · Journal Article
Alhelali HA, Hassan AS 4th, ALZahrani FA, Aljubayri AA, et al.
Open access rheumatology : research and reviews · 2026 · Case Reports
Kanan M, Hasan HA, Hassan AM, Sbitan L
Scientific reports · 2025 · Journal Article
Hashem AF, Yousuf AM, Hassan A
Journal of blood medicine · 2021 · Case Reports
Ibn Idris Rodwan AA, Ahmed Elmansour OK, Ahmed AFE, Elagib EM, et al.
Cureus · 2024 · Journal Article
Alghamdi M, Somaily MY, Alemam S, Majadah S, et al.
BMC musculoskeletal disorders · 2024 · Multicenter Study
Hassan AB, Tayem YI, Sadat-Ali M, Almarabheh AJ, et al.
Journal of medical case reports · 2025 · Journal Article
Karim AK, Gorial FI, Badi IA, Mahdi FJ, et al.
Cureus · 2023 · Case Reports
Abu-Abaa M, Al-Qaysi G, Hassan A, Kananeh S
Cureus · 2024 · Case Reports
Mohammed Alshareef H, Elbarbary A, Hassan AS, Alzahrani FA
Open access rheumatology : research and reviews · 2021 · Journal Article
Abdelgalil Ali Ahmed S, Adam Essa ME, Ahmed AF, Elagib EM, et al.
Metabolites · 2025 · Journal Article
Hassan AB, Hamid RM, Alamien SH, Khalil NA, et al.
Frontiers in neurology · 2026 · Journal Article
Hassan A, Hussein M, Magdy R, Elgenidi A, et al.
The Egyptian journal of immunology · 2022 · Journal Article
Hassan AS, Abdul-Mohymen AM, Ahmed LA, Seliem N, et al.
Scientific reports · 2025 · Journal Article
Hashem AF, Yousuf AM, Hassan A
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026 · Journal Article
Abdalbary M, Amin AM, Elaraby A, Hassan A
International journal of general medicine · 2022 · Journal Article
Nassef EM, Elabd HA, El Nagger BMMA, Elzomor HM, et al.
Pathogens (Basel, Switzerland) · 2024 · Journal Article
Jamshaid M, Heidari A, Hassan A, Mital D, et al.
Medicina (Kaunas, Lithuania) · 2024 · Journal Article
Katamesh BE, Futela P, Vincent A, Thilagar B, et al.
PloS one · 2024 · Journal Article
Serhan HA, Abuawwad MT, Taha MJJ, Hassan AK, et al.
Cureus · 2023 · Journal Article
Alhelali HA, Hassan AS 4th, ALZahrani FA, Aljubayri AA, et al.
Rheumatology international · 2023 · Systematic Review
Hassan AAA, Khalifa AA
Rheumatology international · 2023 · Systematic Review
Hassan AAA, Khalifa AA